KFAS
VRTX icon

Keating Financial Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Keating Financial Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186K Buy
416
+49
+13% +$22.8K 0.03% 340
2025
Q4 		$166K Buy
+367
New +$158K 0.02% 403

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Keating Financial Advisory Services's VRTX Position: Q1 2026 in Review

Keating Financial Advisory Services increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $22.8K and bringing the position to 416 shares worth $186K. The position accounts for 0.03% of the portfolio, ranked #340.

Keating Financial Advisory Services first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Keating Financial Advisory Services held 416 shares of Vertex Pharmaceuticals worth $186K as of Q1 2026.
  • Keating Financial Advisory Services bought 49 Vertex Pharmaceuticals shares in Q1 2026, an estimated $22.8K.
  • Vertex Pharmaceuticals made up 0.03% of Keating Financial Advisory Services's portfolio in Q1 2026, its #340 holding.
  • Keating Financial Advisory Services first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.